New Zealand markets open in 9 hours 58 minutes
  • NZX 50

    11,654.56
    +102.52 (+0.89%)
     
  • NZD/USD

    0.6344
    +0.0046 (+0.74%)
     
  • ALL ORDS

    7,554.00
    +73.30 (+0.98%)
     
  • OIL

    80.93
    +0.38 (+0.47%)
     
  • GOLD

    1,791.70
    +31.80 (+1.81%)
     

Arcturus Therapeutics to Attend the Following Investor Conferences

SAN DIEGO, September 27, 2022--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences.

Jefferies Cell and Genetic Medicine Summit (Attending)

  • Thursday – Friday, September 29 – 30, 2022

Cantor Neurology & Psychiatry Conference (Panel Presentation)

  • Thursday, October 6, 2022 (2:30 – 3:30 p.m. ET)

If available, links can be found under the Investor Relations/Events section of the Arcturus’ website.

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global, late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III, and hepatitis B virus. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations including, amongst others, Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and the Cystic Fibrosis Foundation. In addition, please connect with us on Twitter and LinkedIn. For more information visit www.ArcturusRx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220927006121/en/

Contacts

IR and Media Contacts
Arcturus Therapeutics
IR@arcturusrx.com

Kendall Investor Relations
Carlo Tanzi, Ph.D.
(617) 914-0008
ctanzi@kendallir.com